301 Results

People

  1. Livingston
    Livingston
  2. Old
    Old
  3. Ragupathi
    Ragupathi
  4. Danishefsky
    Danishefsky
  5. Houghton
    Houghton
  6. Gnjatic
    Gnjatic
  7. Jungbluth
    Jungbluth
  8. Wolchok
    Wolchok
  9. Ritter
    Ritter
  10. Scheinberg
    Scheinberg

Groups

  1. Department of Medicine (174)
  2. Solid Tumor Oncology Division (130)
  3. Melanoma and Immunotherapeutics Service (77)
  4. GSK Faculty (76)
  5. Sloan Kettering Institute Faculty (73)
  6. Hematologic Malignancies, Division of (65)
  7. Melanoma Disease Management Team (56)
  8. Center for Hematologic Malignancies (49)
  9. Molecular Pharmacology and Chemistry Program Faculty (46)
  10. Sloan Kettering Institute Postdocs (45)
  1. "immunogenicity"
Formats
  1. Journal Article (262)
  2. Review (16)
  3. Conference Paper (6)
  4. Editorial (6)
  5. Meeting Abstract (6)
  6. Correspondence (2)
  7. Research Letter (2)
  8. Guidelines (1)
Groups
  1. Department of Medicine (174)
  2. Solid Tumor Oncology Division (130)
  3. Melanoma and Immunotherapeutics Service (77)
  4. GSK Faculty (76)
  5. Sloan Kettering Institute Faculty (73)
  6. Hematologic Malignancies, Division of (65)

More Groups

People
  1. Philip Livingston (56)
  2. Lloyd Old (54)
  3. Govindaswami Ragupathi (37)
  4. Jedd Wolchok (26)
  5. Alan Houghton (20)
  6. Samuel Danishefsky (20)

More People

Years
  1. 2025 (12)
  2. 2024 (26)
  3. 2023 (9)
  4. 2022 (9)
  5. 2021 (5)
  6. 2020 (9)

More Years

Publications
  1. Clinical Cancer Research (37)
  2. Proceedings of the National Academy of Sciences of the United States of America (13)
  3. Cancer Research (12)
  4. Cancer Immunology, Immunotherapy (11)
  5. Journal of Immunology (11)
  6. International Journal of Cancer (7)

More Publications

Publishers
  1. American Association for Cancer Research (55)
  2. Nature Publishing Group (29)
  3. Elsevier Inc. (25)
  4. Springer (18)
  5. National Academy of Sciences (13)
  6. John Wiley & Sons (12)

More Publishers

Results (301)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer
    Journal Article

    McHugh, D.; Eisenberger, M.; Heath, E. I.; Bruce, J.; Danila, D. C.; Rathkopf, D. E.; Feldman, J.; Slovin, S. F.; Anand, B.; Chu, R.; more...
    Investigational New Drugs (2019)

    Fulltext@MSK | Save
  • Immunogenic neoantigens derived from gene fusions stimulate T cell responses
    Research Letter

    Yang, W.; Lee, K. W.; Srivastava, R. M.; Kuo, F.; Krishna, C.; Chowell, D.; Makarov, V.; Hoen, D.; Dalin, M. G.; Wexler, L.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer
    Journal Article

    Moore, K. N.; Martin, L. P.; O'Malley, D. M.; Matulonis, U. A.; Konner, J. A.; Vergote, I.; Ponte, J. F.; Birrer, M. J.
    Future Oncology (2018)

    Fulltext@MSK | Save
  • Informatics for cancer immunotherapy
    Journal Article

    Hammerbacher, J.; Snyder, A.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
    Journal Article

    Balachandran, V. P.; Luksza, M.; Zhao, J. N.; Makarov, V.; Moral, J. A.; Remark, R.; Herbst, B.; Askan, G.; Bhanot, U.; Senbabaoglu, Y.; more...
    Nature (2017)

    Fulltext@MSK | Save
  • Human trials of stem cell-derived dopamine neurons for Parkinson's disease: Dawn of a new era
    Journal Article

    Barker, R. A.; Parmar, M.; Studer, L.; Takahashi, J.
    Cell Stem Cell (2017)

    Fulltext@MSK | Save
  • Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival
    Journal Article

    Cheung, I. Y.; Kushner, B. H.; Modak, S.; Basu, E. M.; Roberts, S. S.; Cheung, N. K. V.
    OncoImmunology (2017)

    Fulltext@MSK | Save
  • Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial
    Journal Article

    Tawbi, H. A.; Burgess, M.; Bolejack, V.; Van Tine, B. A.; Schuetze, S. M.; Hu, J.; D'Angelo, S.; Attia, S.; Riedel, R. F.; Priebat, D. A.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • A phase 2, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A Gynecologic Oncology Group partners study
    Journal Article

    Monk, B. J.; Brady, M. F.; Aghajanian, C.; Lankes, H. A.; Rizack, T.; Leach, J.; Fowler, J. M.; Higgins, R.; Hanjani, P.; Morgan, M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A phase I study of unimolecular pentavalent (Globo-H-GM2-sTn-TF-Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission
    Journal Article

    O’Cearbhaill, R. E.; Ragupathi, G.; Zhu, J.; Wan, Q.; Mironov, S.; Yang, G.; Spassova, M. K.; Iasonos, A.; Kravetz, S.; Ouerfelli, O.; more...
    Cancers (2016)

    Fulltext@MSK | Save